Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta‐analysis

Shin, Jin Yong; Roh, Si-Gyun; Lee, Nae-Ho; Yang, Kyung‐Moo

doi:10.1002/hed.24554

Cited by 73 publications

(95 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to other superficial cutaneous sarcomas, angiosarcomas have a poor prognosis with 5‐year survival rates of 10–30 %, primarily due to early hematogenous dissemination. Factors associated with a poorer prognosis, as identified by a recent meta‐analysis, include advanced age (> 70 years), tumor size > 5 cm, incomplete resection, and tumor site (scalp) .…”

Section: Angiosarcomamentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous sarcomas

Kohlmeyer

Steimle-Grauer

Hein

2017

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Cutaneous sarcomas comprise a heterogeneous group of mesenchymal spindle cell tumors of the dermis and subcutis, one of the best-known entities being dermatofibrosarcoma protuberans. Other sarcomas addressed in this review include atypical fibroxanthoma, cutaneous undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. With the exception of dermatofibrosarcoma protuberans, which has its peak incidence in middle-aged adults, cutaneous sarcomas usually occur in elderly individuals starting in the sixth or seventh decade of life. The pathogenesis of the various disease entities is not uniform and has not been definitively ascertained. Histology is the key to arriving at a correct diagnosis, and should always include ruling out other dermal neoplasms such as melanoma. In recent years, molecular genetic methods have provided greater insight into the pathogenesis, thus paving the way for new targeted therapies. Treatment of choice for cutaneous sarcomas is excision with sufficient surgical margins. Adjuvant and neoadjuvant therapeutic concepts include radiation therapy and the use of targeted therapies or chemotherapies. Local recurrences have frequently been reported in cutaneous sarcomas. Unlike soft tissue sarcomas, the prognosis in terms of survival - with the exception of angiosarcoma - is very good if treated adequately, a fact that should be emphasized to patients.

show abstract

Section: Angiosarcomamentioning

confidence: 99%

“…5-Jahres-Überlebensrate von 10-30 % werden angenommen. Als Faktoren, die mit einer schlechteren Prognose einhergehen, wurden kürzlich in einer Metaanalyse hohes Alter (> 70 Jahre), Tumorgröße über 5 cm, inkomplette Resektion und Lokalisation an der Kopfhaut identifi ziert [ 19 ] .…”

Section: Atypisches Fibroxanthomunclassified

Cutaneous sarcomas

Kohlmeyer

Steimle-Grauer

Hein

2017

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Systemic treatment may be used in a neoadjuvant setting, adjuvant setting, and as concurrent treatment with RT. 8,17,18 Conversely, RT plus chemotherapy was not shown to have any prognostic value in a meta-analysis by Shin et al 19 Further studies should be carried out to elucidate the benefit of combined modality treatment.…”

Section: Discussionmentioning

confidence: 98%

Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Chow

Kwan

2018

Hong Kong Med J

View full text Add to dashboard Cite

“…Despite the high probability of recurrence, surgical resection with no residual tumor cell on the margin (R0 resection) remains the mainstay of treatment (Vogt, Brockmeyer, Kutzner, & Schöfer, ). Various researchers have reported that surgery improves the 5‐year survival rate compared with other treatments (odds ratio [OR] = 4.369; p = .002) and positive resection margins are associated with worse overall survival (Shin, Roh, Lee, & Yang, ; Trofymenko & Curiel‐Lewandrowski, ; Vogt et al, ). As ASs are associated with a high chance of recurrence even after complete resection of the tumor, several investigators have used adjuvant radiation therapy to achieve better local control of the disease (Kinard, Zwicker, Schmidt‐Ullrich, Kaufman, & Pieters, ; Scott et al, ).…”

Section: Discussionmentioning

confidence: 99%

Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options

Goldust

Giulini

Weidenthaler-Barth

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Angiosarcomas (ASs) are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy or chronic lymphedema. With only 1–5% of all sarcomas, the incidence seems low, but for the affected patient due to the extremely poor prognosis and the limited treatment options, the fate is often inevitable. Radiotherapy, chemotherapy, or “target therapy” have been used in the management of AS, but represent individual case decisions without lasting evidence. Over the past few years, breast‐conserving surgery followed by radiation therapy, known as breast‐conserving therapy (BCT), is being employed as a standard treatment for early‐stage breast cancer, but there has been an increase in reports of AS following BCT. We report two cases of AS following BCT and one case of primary AS involving the lower limb.

show abstract

Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta‐analysis

Abstract: Although further investigation of long-term and prospective studies is needed, we identified 5 variables as predisposing factors for poor prognosis of angiosarcoma through meta-analysis. © 2016 Wiley Periodicals, Inc. Head Neck 39: 380-386, 2017.

Cited by 73 publications

References 33 publications

Cutaneous sarcomas

Cutaneous sarcomas

Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options

Contact Info

Product

Resources

About